$MorphoSys(MOR.US)$MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition" Benzinga· 5 mins ago Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com) Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.
$MorphoSys(MOR.US)$MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, ...
$MorphoSys(MOR.US)$stock is falling hard on Tuesday after the company released data from a Phase 3 clinical trial of pelabresib. The study evaluated pelabresib as a treatment for myelofibrosis in combination with ruxolitinib. It included patients treated with these two drugs as well as a placebo arm just treated with ruxolitinib. The results from the clinical trial saw pelabresib meet its primary endpoint. There was also statistical significance observed ...
$MorphoSys(MOR.US)$The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.
$MorphoSys(MOR.US)$MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Implied volatility is a measure of the market's expectation of the potential price movements of the stock in the future. Here are the stocks with the most notable implied volatility today. $MorphoSys(MOR.US)$'s stock remained unchanged during the previous trading session. However, options volume was notable at 3.93K and the implied volatility percentile stood at an impressive 96.0%. This means that option traders are anticipating a signif...
Jaguar8 : 格羅爾
Jaguar8 : 即使是虛假新聞在股市上也有很多
Trytosaveabit樓主 Jaguar8: 是的是啊!它無處不在